{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:09:17Z","timestamp":1788822557512,"version":"build-2803163510"},"reference-count":58,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100005570","name":"Takeda Pharmaceuticals North America","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005570","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014480","name":"Horizon Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014480","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Medical Clinics of North America"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.mcna.2020.09.013","type":"journal-article","created":{"date-parts":[[2021,1,14]],"date-time":"2021-01-14T10:18:02Z","timestamp":1610619482000},"page":"297-310","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":46,"title":["Management and Cure of Gouty Arthritis"],"prefix":"10.1016","volume":"105","author":[{"given":"Sarah F.","family":"Keller","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian F.","family":"Mandell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.mcna.2020.09.013_bib1","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/art.40807","article-title":"Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007\u20132016","volume":"71","author":"Chen-Xu","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"13","key":"10.1016\/j.mcna.2020.09.013_bib2","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1001\/archinternmed.2010.196","article-title":"A\u00a0diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis","volume":"170","author":"Janssens","year":"2010","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.mcna.2020.09.013_bib3","series-title":"Imaging in rheumatology: a clinical approach","first-page":"269","article-title":"Metabolic, endocrine, and crystal deposition arthropathies","author":"Greenspan","year":"2018"},{"key":"10.1016\/j.mcna.2020.09.013_bib4","series-title":"Arthritis in black and white","first-page":"293","article-title":"Gout","author":"Brower","year":"2012"},{"key":"10.1016\/j.mcna.2020.09.013_bib5","series-title":"Musculoskeletal ultrasound in rheumatology review","first-page":"23","article-title":"Basic ultrasound pathology","author":"Samuels","year":"2016"},{"key":"10.1016\/j.mcna.2020.09.013_bib6","series-title":"Essential imaging in rheumatology","first-page":"213","article-title":"Crystal-related disease","author":"O\u2019Neill","year":"2015"},{"issue":"12","key":"10.1016\/j.mcna.2020.09.013_bib7","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1093\/rheumatology\/kez180","article-title":"The diagnostic performance of dual energy CT for diagnosing gout: a systematic literature review and meta-analysis","volume":"58","author":"Gamala","year":"2019","journal-title":"Rheumatol"},{"issue":"6","key":"10.1016\/j.mcna.2020.09.013_bib8","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology Guideline for the Management of Gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.mcna.2020.09.013_bib9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"17","key":"10.1016\/j.mcna.2020.09.013_bib10","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1056\/NEJMcp030733","article-title":"Clinical practice. Gout","volume":"349","author":"Terkeltaub","year":"2003","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mcna.2020.09.013_bib11","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1136\/annrheumdis-2019-216154","article-title":"Open-label randomised pragmatic trial (CONTACT) comparing naproxen and low-dose colchicine for the treatment of gout flares in primary care","volume":"79","author":"Roddy","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.mcna.2020.09.013_bib12","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.3899\/jrheum.110916","article-title":"Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: a randomized controlled trial","volume":"39","author":"Schumacher","year":"2012","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.mcna.2020.09.013_bib13","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1136\/annrheumdis-2014-206410","article-title":"Comorbidities in patients with gout prior to and following diagnosis: case-control study","volume":"75","author":"Kuo","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.mcna.2020.09.013_bib14","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1002\/art.27327","article-title":"High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study","volume":"62","author":"Terkeltaub","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.mcna.2020.09.013_bib15","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/nrrheum.2009.236","article-title":"Update on gout: new therapeutic strategies and options","volume":"6","author":"Terkeltaub","year":"2010","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1016\/j.mcna.2020.09.013_bib16","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.amjmed.2014.12.010","article-title":"Colchicine: old and new","volume":"128","author":"Slobodnick","year":"2015","journal-title":"Am J Med"},{"key":"10.1016\/j.mcna.2020.09.013_bib17","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1016\/S0140-6736(08)60799-0","article-title":"Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial","volume":"371","author":"Janssens","year":"2008","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.mcna.2020.09.013_bib18","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.annemergmed.2006.11.014","article-title":"Comparison of oral prednisolone\/paracetamol and oral indomethacin\/paracetamol combination therapy in the treatment of acute goutlike arthritis: a double-blind, randomized, controlled trial","volume":"49","author":"Man","year":"2007","journal-title":"Ann Emerg Med"},{"issue":"1","key":"10.1016\/j.mcna.2020.09.013_bib19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/imr.12286","article-title":"Initiation and perpetuation of NLRP3 inflammasome activation and assembly","volume":"265","author":"Elliott","year":"2015","journal-title":"Immunol Rev"},{"issue":"7081","key":"10.1016\/j.mcna.2020.09.013_bib20","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"},{"issue":"23","key":"10.1016\/j.mcna.2020.09.013_bib21","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1001\/jama.1994.03510470040032","article-title":"Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome. Results from a randomized, double-blind, placebo-controlled trial. Phase III rhIL-1ra Sepsis Syndrome Study Group","volume":"271","author":"Fisher","year":"1994","journal-title":"JAMA"},{"issue":"10","key":"10.1016\/j.mcna.2020.09.013_bib22","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.3899\/jrheum.181018","article-title":"Use of anakinra in hospitalized patients with crystal-associated arthritis","volume":"46","author":"Liew","year":"2019","journal-title":"J\u00a0Rheumatol"},{"issue":"9","key":"10.1016\/j.mcna.2020.09.013_bib23","doi-asserted-by":"crossref","first-page":"e017121","DOI":"10.1136\/bmjopen-2017-017121","volume":"7","author":"Balasubramaniam","year":"2017","journal-title":"BMJ Open"},{"issue":"SUPPL.5","key":"10.1016\/j.mcna.2020.09.013_bib24","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3949\/ccjm.75.Suppl_5.S5","article-title":"Clinical manifestations of hyperuricemia and gout","volume":"75","author":"Mandell","year":"2008","journal-title":"Cleve Clin J Med"},{"issue":"5","key":"10.1016\/j.mcna.2020.09.013_bib25","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/annrheumdis-2013-203970","article-title":"Impact of bariatric surgery on serum urate targets in people with morbid obesity and diabetes: a prospective longitudinal study","volume":"73","author":"Dalbeth","year":"2014","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.mcna.2020.09.013_bib26","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1056\/NEJMoa035700","article-title":"Purine-rich foods, daily and protein intake, and the risk of gout in men","volume":"350","author":"Choi","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"9417","key":"10.1016\/j.mcna.2020.09.013_bib27","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(04)16000-5","article-title":"Alcohol intake and risk of incident gout in men: a prospective study","volume":"363","author":"Choi","year":"2004","journal-title":"Lancet"},{"issue":"7639","key":"10.1016\/j.mcna.2020.09.013_bib28","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1136\/bmj.39449.819271.BE","article-title":"Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study","volume":"336","author":"Choi","year":"2008","journal-title":"BMJ"},{"issue":"SUPPL.5","key":"10.1016\/j.mcna.2020.09.013_bib29","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3949\/ccjm.75.Suppl_5.S2","article-title":"The pathogenesis of gout","volume":"75","author":"Schumacher","year":"2008","journal-title":"Cleve Clin J Med"},{"issue":"3","key":"10.1016\/j.mcna.2020.09.013_bib30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/art.20405","article-title":"A\u00a0retrospective study of the relationship between serum urate level and recurrent attacks of gouty arthritis: evidence for reduction of recurrent gouty arthritis with antihyperuricemic therapy","volume":"51","author":"Shoji","year":"2004","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"10.1016\/j.mcna.2020.09.013_bib31","doi-asserted-by":"crossref","first-page":"589","DOI":"10.3949\/ccjm.69.8.589","article-title":"Hyperuricemia and gout: a reign of complacency","volume":"69","author":"Mandell","year":"2002","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.mcna.2020.09.013_bib32","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-1-4615-5381-6_3","article-title":"Optimal range of serum urate concentrations to minimize risk of gouty attacks during anti-hyperuricemic treatment","volume":"431","author":"Yamanaka","year":"1998","journal-title":"Adv Exp Med Biol"},{"issue":"7","key":"10.1016\/j.mcna.2020.09.013_bib33","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1001\/jama.2011.1169","article-title":"Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials","volume":"306","author":"Sundy","year":"2011","journal-title":"J\u00a0Am Med Assoc"},{"issue":"SUPPL.5","key":"10.1016\/j.mcna.2020.09.013_bib34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3949\/ccjm.75.Suppl_5.S13","article-title":"The role of hyperuricemia and gout in kidney and cardiovascular disease","volume":"75","author":"Edwards","year":"2008","journal-title":"Cleve Clin J Med"},{"issue":"3","key":"10.1016\/j.mcna.2020.09.013_bib35","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1053\/j.ajkd.2017.01.055","article-title":"Management of Gout and Hyperuricemia in CKD","volume":"70","author":"Vargas-Santos","year":"2017","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"10.1016\/j.mcna.2020.09.013_bib36","doi-asserted-by":"crossref","first-page":"280","DOI":"10.4103\/0971-4065.114499","article-title":"Allopurinol for prevention of progression of kidney disease with hyperuricemia","volume":"23","author":"Santhosh Pai","year":"2013","journal-title":"Indian J Nephrol"},{"issue":"5","key":"10.1016\/j.mcna.2020.09.013_bib37","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3899\/jrheum.131159","article-title":"Effect of urate-lowering therapies on renal disease progression in patients with hyperuricemia","volume":"41","author":"Levy","year":"2014","journal-title":"J\u00a0Rheumatol"},{"issue":"1","key":"10.1016\/j.mcna.2020.09.013_bib38","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1097\/RHU.0b013e318204aab4","article-title":"Renal function in gout: long-term treatment effects of febuxostat","volume":"17","author":"Whelton","year":"2011","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"6","key":"10.1016\/j.mcna.2020.09.013_bib39","first-page":"403","article-title":"Does hyperuricemia affect mortality? A prospective cohort study of Japanese male workers","volume":"10","author":"Tomita","year":"2000","journal-title":"J\u00a0Epidemiol"},{"issue":"4","key":"10.1016\/j.mcna.2020.09.013_bib40","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/S0272-6386(04)00934-5","article-title":"Significance of hyperuricemia as a risk factor for developing ESRD in a screened cohort","volume":"44","author":"Iseki","year":"2004","journal-title":"Am J Kidney Dis"},{"issue":"26","key":"10.1016\/j.mcna.2020.09.013_bib41","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1056\/NEJMe2015886","article-title":"Urate-Lowering Therapy and Chronic Kidney Disease Progression","volume":"382","author":"Feig","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.mcna.2020.09.013_bib42","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/art.23121","article-title":"Serum uric acid is an independent predictor of all-cause mortality in patients at high risk of cardiovascular disease: a Preventive Cardiology Information System (PreCIS) database cohort study","volume":"58","author":"Ioachimescu","year":"2008","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.mcna.2020.09.013_bib43","doi-asserted-by":"crossref","first-page":"e001015","DOI":"10.1136\/rmdopen-2019-001015","article-title":"Failure to reach uric acid target of <0.36\u00a0mmol\/L in hyperuricaemia of gout is associated with elevated total and cardiovascular mortality","volume":"5","author":"P\u00e9rez Ruiz","year":"2019","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.mcna.2020.09.013_bib44","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12872-016-0379-z","article-title":"Hyperuricemia and coronary heart disease mortality: a meta-analysis of prospective cohort studies","volume":"16","author":"Zuo","year":"2016","journal-title":"BMC Cardiovasc Disord"},{"issue":"2","key":"10.1016\/j.mcna.2020.09.013_bib45","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/art.24164","article-title":"Serum uric acid level as an independent risk factor for all-cause, cardiovascular, and ischemic stroke mortality: a Chinese cohort study","volume":"61","author":"Chen","year":"2009","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.mcna.2020.09.013_bib46","doi-asserted-by":"crossref","first-page":"S24","DOI":"10.1016\/j.semarthrit.2020.04.010","article-title":"Therapeutic approaches in the treatment of gout","volume":"50","author":"Pillinger","year":"2020","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"10.1016\/j.mcna.2020.09.013_bib47","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1136\/annrheumdis-2016-210872","article-title":"A\u00a0randomised controlled trial of the efficacy and safety of allopurinol dose escalation to achieve target serum urate in people with gout","volume":"76","author":"Stamp","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.mcna.2020.09.013_bib48","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1001\/jamainternmed.2015.3536","article-title":"Allopurinol use and risk of fatal hypersensitivity reactions a nationwide population-based study in Taiwan","volume":"175","author":"Yang","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"8","key":"10.1016\/j.mcna.2020.09.013_bib49","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1136\/annrheumdis-2017-212905","article-title":"Racial\/ethnic variation and risk factors for allopurinol-associated severe cutaneous adverse reactions: a cohort study","volume":"77","author":"Keller","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.mcna.2020.09.013_bib50","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1002\/art.34488","article-title":"Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol","volume":"64","author":"Stamp","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"23","key":"10.1016\/j.mcna.2020.09.013_bib51","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1056\/NEJMoa050373","article-title":"Febuxostat compared with allopurinol in patients with hyperuricemia and gout","volume":"353","author":"Becker","year":"2005","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.mcna.2020.09.013_bib52","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","article-title":"Cardiovascular safety of febuxostat or allopurinol in patients with gout","volume":"378","author":"White","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.mcna.2020.09.013_bib53","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/rheumatology\/kex350","article-title":"Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6\u00a0month phase 3 clinical trial and extension study","volume":"56","author":"Tausche","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"10.1016\/j.mcna.2020.09.013_bib54","first-page":"2429","article-title":"Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis","volume":"31","author":"Borstad","year":"2004","journal-title":"J\u00a0Rheumatol"},{"issue":"5","key":"10.1016\/j.mcna.2020.09.013_bib55","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/art.1780170517","article-title":"Prophylactic colchicine therapy of intercritical gout. A placebo-controlled study of probenecid-treated patients","volume":"17","author":"Paulus","year":"1974","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.mcna.2020.09.013_bib56","doi-asserted-by":"crossref","DOI":"10.1186\/ar4318","article-title":"Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy","volume":"15","author":"Baraf","year":"2013","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"10.1016\/j.mcna.2020.09.013_bib57","doi-asserted-by":"crossref","first-page":"R137","DOI":"10.1186\/s13075-018-1782-x","article-title":"Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase","volume":"20","author":"Mandell","year":"2018","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"10.1016\/j.mcna.2020.09.013_bib58","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.3899\/jrheum.111375","article-title":"Improved health-related quality of life and physical function in patients with refractory chronic gout following treatment with pegloticase: evidence from phase III randomized controlled trials","volume":"39","author":"Strand","year":"2012","journal-title":"J\u00a0Rheumatol"}],"container-title":["Medical Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712520301255?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025712520301255?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T01:44:54Z","timestamp":1758419094000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025712520301255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":58,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S0025712520301255"],"URL":"https:\/\/doi.org\/10.1016\/j.mcna.2020.09.013","relation":{},"ISSN":["0025-7125"],"issn-type":[{"value":"0025-7125","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management and Cure of Gouty Arthritis","name":"articletitle","label":"Article Title"},{"value":"Medical Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mcna.2020.09.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}